Keywords: Biogen Idec, Isis Pharma, Collaboration agreement, Neuromuscular disorders, Antisense drugs

Biogen Idec and Isis Pharma in up to $230 million antisense deal

Article | 11 December 2012

USA-based companies Biogen Idec (Nasdaq: BIIB) and Isis Pharmaceuticals (Nasdaq: ISIS) have entered into a global collaboration agreement under which ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Biogen Idec

Isis Pharmaceuticals

Go to company listing